BioPharmX Corp BPMX Cash Flow

Biopharmx corp (BPMX)

CashFlow / TTM

Jan'20	Oct'19	Jul'19	Apr'19	Jan'19	Oct'18	Jul'18	Apr'18	Jan'18	Oct'17	Jul'17	Apr'17	Jan'17	Oct'16	Jul'16	Apr'16	Jan'16	Oct'15	Jul'15	Apr'15	Dec'14	Sep'14	Jul'14	Jun'14	Apr'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10
Cash flows from operating activities:
Net loss
-9,687	-12,438	-14,715	-16,479	-17,258	-16,990	-16,314	-15,645	-16,640	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-59	0	0	0
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-16,435	-15,598	-13,821	-12,036	-10,278	-7,807	-5,797	-	-4,183	0	-2,632	-1,588	0	0	0	-	-	-	-	-	-	-	-	-
Net loss for the period
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-52	-26	-26	-29	-27	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
741	901	1,390	1,659	2,061	2,228	1,975	2,095	1,887	1,863	1,745	1,603	1,491	1,392	1,287	1,187	1,214	1,674	1,504	1,461	1,193	415	-	360	0	85	58	0	0	0	-	-	-	-	-	-	-	-	-
Fair value of modification of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	436	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
61	60	59	60	62	62	61	56	52	128	132	137	141	71	68	64	56	51	42	32	25	9	-	5	0	5	5	6	4	1	0	0	0	0	0	0	0	0	0
Amortization expense
-	-	-	-	-	-	-	-	-	-	-	-	119	30	30	30	30	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-	0	0	103	-	33	160	662	364	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-32	0	6	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
-	-	-	-	-	-	-	-	-	-62	-92	-46	-62	-259	-252	-139	-60	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-63	-50	-105	17	32	-207	44	-82	-75	0	0	0	-	-	-	-	46	7	-43	1,010	133	-209	-	167	0	-165	-184	0	0	0	-	-	-	-	-	-	-	-	-
Accounts payable
-799	-700	-589	-607	-13	-619	-844	-516	-1,175	-829	-1,046	-86	774	1,074	87	150	625	0	0	0	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-594	-1,000	-643	-111	-661	-52	37	-517	427	-208	371	830	156	1,130	127	102	608	0	0	0	-	-	-	-	-	-	-	44	18	15	16	16	50	52	52	53	0	0	0
Accrued expenses and other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,224	-	702	-	432	446	0	0	0	-	-	-	-	-	-	-	-	-
Payroll
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Related party payables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	-195	-86	67	74	206	-	279	0	172	109	0	0	0	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13,962	-12,614	0	0	0	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued interest - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	-	-	-	-
Net cash used in operating activities
-10,107	-12,290	-13,598	-14,721	-14,992	-15,216	-15,158	-14,965	-15,587	0	0	0	-	-	-	-	-	-	-	-	-	-3,907	-	-3,135	-	-2,003	-1,080	-675	-270	-41	-12	-10	-6	-7	-5	-5	0	0	0
Cash flows from investing activities:
Purchases of property and equipment
30	60	69	45	43	13	17	35	41	66	52	50	45	0	0	0	-	-	-	-	228	167	-	36	0	35	25	24	10	0	0	0	1	1	1	0	0	0	0
Net cash used in investing activities
-30	-60	-69	-45	-43	-13	-17	-35	-41	0	0	0	-	-	-	-	-	-	-	-	-	-212	-	-81	-	-45	-85	0	0	0	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs
7,200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-
Purchase of intellectual property
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	60	0	0	0	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the issuance of common stock, preferred stock and warrants, net of issuance costs
-	-	-	-	-	-	-	-	16,049	17,392	19,484	17,573	16,712	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	15	15	0	0	0
Proceeds from exercises of common stock warrants
-	-	-	-	10,546	0	0	0	-	-	-	-	-	-	-	-	1,487	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercises of stock options
4	4	4	4	1	0	0	0	-	-	-	-	41	76	83	90	83	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on financing lease obligation
34	30	24	20	19	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of convertible redeemable preferred stock and common stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,020	1,420	-	1,793	0	2,000	1,030	633	0	0	0	-	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,564	15,386	0	0	0	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
7,795	10,759	10,376	7,123	10,528	16,671	17,291	19,217	16,703	0	0	0	-	-	-	-	-	-	-	-	-	5,303	-	4,020	-	2,000	1,030	633	0	0	0	-	-	-	0	-	-	-	-
Net decrease in cash and cash equivalents
-2,342	-1,591	-3,291	-7,643	-4,507	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing activities:
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	1,075	1,108	4,029	2,671	2,462	-1,713	-6,952	3,559	2,734	1,779	7,320	1,228	2,108	1,184	-	804	0	-48	-135	0	0	0	-	-	-	-	-	-	-	-	-
Supplemental disclosures:
Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0
Income taxes paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
NET INCREASE IN CASH
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4	-4	-7	-9	-10	-5	-7	9	8	0	0	0